These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 31804741)

  • 1. The prompt use of rituximab could decrease adverse effects in patient with pemphigus vulgaris: A preliminary evaluation.
    Arduino PG; Broccoletti R; Carbone M; Conrotto D; Sciannameo V; Gambino A; Cabras M; Carrozzo M; Baldovino S
    J Oral Pathol Med; 2020 Feb; 49(2):177-180. PubMed ID: 31804741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First line treatment of pemphigus vulgaris with a novel protocol in patients with contraindications to systemic corticosteroids and immunosuppressive agents: Preliminary retrospective study with a seven year follow-up.
    Ahmed AR; Nguyen T; Kaveri S; Spigelman ZS
    Int Immunopharmacol; 2016 May; 34():25-31. PubMed ID: 26919279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing early and late treatments with rituximab in pemphigus vulgaris: which one is better?
    Balighi K; Daneshpazhooh M; Mahmoudi H; Badakhsh M; Teimourpour A; Ehsani AH; Azizpour A; Akbari Z; Mahdavinia M; Ghasemiadl M; Tavakolpour S
    Arch Dermatol Res; 2019 Jan; 311(1):63-69. PubMed ID: 30506422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective analysis of a single-center clinical experience toward development of curative treatment of 123 pemphigus patients with a long-term follow-up: efficacy and safety of the multidrug protocol combining intravenous immunoglobulin with the cytotoxic immunosuppressor and mitochondrion-protecting drugs.
    Grando SA
    Int J Dermatol; 2019 Jan; 58(1):114-125. PubMed ID: 30047585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of rituximab as an adjuvant in the treatment of oral pemphigus vulgaris.
    Fortuna G; Calabria E; Ruoppo E; Adamo D; Aria M; Amato M; Mignogna MD
    J Oral Pathol Med; 2020 Jan; 49(1):91-95. PubMed ID: 31420993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab therapy in pediatric pemphigus patients: A retrospective analysis of five Turkish patients and review of the literature.
    Bilgic-Temel A; Özgen Z; Harman M; Kapıcıoğlu Y; Uzun S
    Pediatr Dermatol; 2019 Sep; 36(5):646-650. PubMed ID: 31355479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple cycles of rituximab therapy for pemphigus: A group of patients with difficult- to-treat disease or a consequence of late rituximab initiation?
    Balighi K; Hatami P; Sheikh Aboli MJ; Daneshpazhooh M; Ghiasi M; Mahmoudi HR; Aryanian Z
    Dermatol Ther; 2022 Feb; 35(2):e15249. PubMed ID: 34910350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect.
    Chen DM; Odueyungbo A; Csinady E; Gearhart L; Lehane P; Cheu M; Maho-Vaillant M; Prost-Squarcioni C; Hebert V; Houivet E; Calbo S; Caillot F; Golinski ML; Labeille B; Picard-Dahan C; Paul C; Richard MA; Bouaziz JD; Duvert-Lehembre S; Bernard P; Caux F; Alexandre M; Ingen-Housz-Oro S; Vabres P; Delaporte E; Quereux G; Dupuy A; Debarbieux S; Avenel-Audran M; D'Incan M; Bedane C; Bénéton N; Jullien D; Dupin N; Misery L; Machet L; Beylot-Barry M; Dereure O; Sassolas B; Benichou J; Musette P; Joly P;
    Br J Dermatol; 2020 May; 182(5):1111-1119. PubMed ID: 31487383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current biologics in treatment of pemphigus foliaceus: a systematic review.
    Carver CA; Kalesinskas M; Ahmed AR
    Front Immunol; 2023; 14():1267668. PubMed ID: 37901249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of biosimilar rituximab in patients with pemphigus vulgaris: a prospective observational study.
    Toosi R; Mahmoudi H; Balighi K; Teimourpour A; Alaeen H; Shaghaghi M; Abedini R; Daneshpazhooh M
    J Dermatolog Treat; 2021 Feb; 32(1):33-40. PubMed ID: 31074302
    [No Abstract]   [Full Text] [Related]  

  • 11. Rituximab treatment of severe pemphigus: long-term results including immunologic follow-up.
    Reguiai Z; Tabary T; Maizières M; Bernard P
    J Am Acad Dermatol; 2012 Oct; 67(4):623-9. PubMed ID: 22261417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab in practice: Clinical evaluation of patients with pemphigus after rituximab administration.
    Mahmoudi H; Tavakolpour S; Balighi K; Farid AS; Nili A; Jan D; Daneshpazhooh M
    Dermatol Ther; 2021 Jan; 34(1):e14633. PubMed ID: 33280226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unexpected worsening of pemphigus vulgaris after rituximab: A report of three cases.
    Mahmoudi H; Balighi K; Tavakolpour S; Daneshpazhooh M
    Int Immunopharmacol; 2019 Jun; 71():40-42. PubMed ID: 30877872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab and low dose oral immune modulating treatment to maintain a sustained response in severe pemphigus patients.
    Keeley JM; Bevans SL; Jaleel T; Sami N
    J Dermatolog Treat; 2019 Jun; 30(4):340-345. PubMed ID: 30086663
    [No Abstract]   [Full Text] [Related]  

  • 15. [Use of rituximab in maintenance treatment of pemphigus: A retrospective series].
    Barroil M; Girard C; Lerisson M; Negroni V; Bertrand AS; Pallure V; Bessis D; Guillot B; Dereure O
    Ann Dermatol Venereol; 2020 Mar; 147(3):173-178. PubMed ID: 31955970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Pediatric Pemphigus Foliaceus.
    Carver C; Kalesinskas M; Dheden N; Ahmed AR
    Cureus; 2023 Sep; 15(9):e45373. PubMed ID: 37779684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant rituximab therapy in pemphigus: a single-center experience of 18 cases.
    Baum S; Gilboa S; Greenberger S; Pavlotsky F; Trau H; Barzilai A
    J Dermatolog Treat; 2013 Dec; 24(6):427-30. PubMed ID: 23521340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intralesional Rituximab in the Treatment of Refractory Oral Pemphigus Vulgaris.
    Vinay K; Kanwar AJ; Mittal A; Dogra S; Minz RW; Hashimoto T
    JAMA Dermatol; 2015 Aug; 151(8):878-82. PubMed ID: 25536513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult-to-treat pemphigus vulgaris.
    Behzad M; Möbs C; Kneisel A; Möller M; Hoyer J; Hertl M; Eming R
    Br J Dermatol; 2012 Apr; 166(4):844-52. PubMed ID: 22092243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iranian guideline for rituximab therapy in pemphigus patients.
    Daneshpazhooh M; Balighi K; Mahmoudi H; Tavakolpour S; Abedini R; Soori T; Ehsani AH; Ghiasi M; Noormohammadpour P; Ghandi N; Lajevardi V; Sadeghinia A; Nasimi M; Azizpour A; Chams-Davatchi C
    Dermatol Ther; 2019 Sep; 32(5):e13016. PubMed ID: 31269316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.